Bioinformatic Analysis of the Effects and Mechanisms of Decitabine and Cytarabine on Acute Myeloid Leukemia

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2017 May 13

PMID 28498449

Citations 3

Authors

Shiyong Zhou

Pengfei Liu

Huilai Zhang

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is a frequently occurring malignant disease of the blood and may result from a variety of genetic disorders. The present study aimed to identify the underlying mechanisms associated with the therapeutic effects of decitabine and cytarabine on AML, using microarray analysis. The microarray datasets GSE40442 and GSE40870 were downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) and differentially methylated sites were identified in AML cells treated with decitabine compared with those treated with cytarabine via the Linear Models for Microarray Data package, following data pre‑processing. Gene Ontology (GO) analysis of DEGs was performed using the Database for Annotation, Visualization and Integrated Analysis Discovery. Genes corresponding to the differentially methylated sites were obtained using the annotation package of the methylation microarray platform. The overlapping genes were identified, which exhibited the opposite variation trend between gene expression and DNA methylation. Important transcription factor (TF)‑gene pairs were screened out, and a regulated network subsequently constructed. A total of 190 DEGs and 540 differentially methylated sites were identified in AML cells treated with decitabine compared with those treated with cytarabine. A total of 36 GO terms of DEGs were enriched, including nucleosomes, protein‑DNA complexes and the nucleosome assembly. The 540 differentially methylated sites were located on 240 genes, including the acid‑repeat containing protein (ACRC) gene that was additionally differentially expressed. In addition, 60 TF pairs and overlapped methylated sites, and 140 TF‑pairs and DEGs were screened out. The regulated network included 68 nodes and 140 TF‑gene pairs. The present study identified various genes including ACRC and proliferating cell nuclear antigen, in addition to various TFs, including TATA‑box binding protein associated factor 1 and CCCTC‑binding factor, which may be potential therapeutic targets of AML.

Citing Articles

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.

Zhao M, DiPeri T, Raso M, Zheng X, Rizvi Y, Evans K NPJ Breast Cancer. 2023; 9(1):66.

PMID: 37567892 PMC: 10421911. DOI: 10.1038/s41523-023-00573-8.

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.

Kong X, Zhang X, Ding M, Feng X, Dong M, Zhang L Cancer Med. 2023; 12(7):8134-8143.

PMID: 36695162 PMC: 10134321. DOI: 10.1002/cam4.5615.

Expression and prognostic potential of GPX1 in human cancers based on data mining.

Wei R, Qiu H, Xu J, Mo J, Liu Y, Gui Y Ann Transl Med. 2020; 8(4):124.

PMID: 32175417 PMC: 7049064. DOI: 10.21037/atm.2020.02.36.

References

Ben Abdelali R, Roggy A, Leguay T, Cieslak A, Renneville A, Touzart A . SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. Blood. 2014; 123(12):1860-3. DOI: 10.1182/blood-2013-08-521518. View

Gautier L, Cope L, Bolstad B, Irizarry R . affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15. DOI: 10.1093/bioinformatics/btg405. View

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic J . Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood. 2014; 123(13):2066-74. DOI: 10.1182/blood-2012-12-469833. View

Wang E . Treating acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program. 2015; 2014(1):14-20. DOI: 10.1182/asheducation-2014.1.14. View

Taga T, Tomizawa D, Takahashi H, Adachi S . Acute myeloid leukemia in children: Current status and future directions. Pediatr Int. 2015; 58(2):71-80. DOI: 10.1111/ped.12865. View

Kadia T, Ravandi F, Cortes J, Kantarjian H . New drugs in acute myeloid leukemia. Ann Oncol. 2016; 27(5):770-8. PMC: 4843183. DOI: 10.1093/annonc/mdw015. View

Marcucci G, Haferlach T, Dohner H . Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011; 29(5):475-86. DOI: 10.1200/JCO.2010.30.2554. View

Wang D, Yan L, Hu Q, Sucheston L, Higgins M, Ambrosone C . IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics. 2012; 28(5):729-30. PMC: 3289916. DOI: 10.1093/bioinformatics/bts013. View

10.

Feinberg A . Phenotypic plasticity and the epigenetics of human disease. Nature. 2007; 447(7143):433-40. DOI: 10.1038/nature05919. View

11.

Lowenberg B . Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013; 121(1):26-8. DOI: 10.1182/blood-2012-07-444851. View

12.

Hu Y, Liu F, Lin I, Gao G, Zhu B . Dissemination of the mcr-1 colistin resistance gene. Lancet Infect Dis. 2015; 16(2):146-7. DOI: 10.1016/S1473-3099(15)00533-2. View

13.

Durinck S, Spellman P, Birney E, Huber W . Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009; 4(8):1184-91. PMC: 3159387. DOI: 10.1038/nprot.2009.97. View

14.

Hu S, Wan J, Su Y, Song Q, Zeng Y, Nguyen H . DNA methylation presents distinct binding sites for human transcription factors. Elife. 2013; 2:e00726. PMC: 3762332. DOI: 10.7554/eLife.00726. View

15.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

16.

Curran M . Decitabine: a review of its use in older patients with acute myeloid leukaemia. Drugs Aging. 2013; 30(6):447-58. DOI: 10.1007/s40266-013-0084-x. View

17.

Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S . The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009; 23(6):1019-28. DOI: 10.1038/leu.2008.397. View

18.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

19.

Weaver I, Hellstrom I, Brown S, Andrews S, Dymov S, Diorio J . The methylated-DNA binding protein MBD2 enhances NGFI-A (egr-1)-mediated transcriptional activation of the glucocorticoid receptor. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1652). PMC: 4142034. DOI: 10.1098/rstb.2013.0513. View

20.

Nestheide S, Bridge J, Barnes M, Frayer R, Sumegi J . Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma. Pediatr Blood Cancer. 2013; 60(9):1437-46. DOI: 10.1002/pbc.24526. View